Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT07215637 | Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 60 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT06809114 | FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors | recruiting | Phase 1 | 83 | Axcynsis Therapeutics Pte LtdINDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07377591 | A Study of HDM2006 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 48 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06644300 | Study of BM230 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 123 | Suzhou Biomissile Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 29, 2026 | clinicaltrials |
| NCT07148128 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | recruiting | Phase 1 / Phase 2 | 110 | Auricula Biosciences Inc.INDUSTRY | 3 | Jan 29, 2026 | clinicaltrials |
| NCT05371132 | Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) | recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | recruiting | Phase 1 / Phase 2 | 90 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT06484985 | Study of AXT-1003 in Subjects With Advanced Malignant Tumors. | recruiting | Phase 1 | 78 | Axter Therapeutics (Beijing) Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05867420 | A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 594 | AskGene Pharma, Inc.INDUSTRY | 2 | Jan 27, 2026 | clinicaltrials |
| NCT07348211 | First in Human Study of SIM0610 in Solid Tumors(SIM0610-101) | recruiting | Phase 1 | 260 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07093970 | A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 343 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06503783 | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06609187 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06612840 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06959615 | A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration | recruiting | Phase 1 / Phase 2 | 334 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07351903 | A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors(GUARDIAN-02) | recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06302426 | Trial of INI-4001 in Patients With Advanced Solid Tumours | recruiting | Phase 1 | 50 | Inimmune CorporationINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06927570 | A Study of HS-20122 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 1,050 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06973564 | JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration | recruiting | Phase 1 / Phase 2 | 294 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07186452 | Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 18 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07231458 | A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies | recruiting | Phase 1 | 27 | Abalos Therapeutics GmbHINDUSTRY | 2 | Jan 16, 2026 | clinicaltrials |
| NCT07348042 | Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors | recruiting | Phase 1 | 198 | Xian-Jun YuOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07275242 | A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor | recruiting | Phase 1 | 107 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06234423 | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 263 | OnCusp Therapeutics, Inc.INDUSTRY | 2 | Jan 14, 2026 | clinicaltrials |
| NCT07253116 | A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 20 | Nanjing Jingao biomidical technology Co. Ltd.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07312903 | DPTX3186 in Wnt Pathway Activated Solid Tumors | recruiting | Phase 1 | 40 | Dewpoint TherapeuticsINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06737731 | A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT06990464 | A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients | recruiting | Phase 1 | 156 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07131202 | A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 130 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06235437 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 | recruiting | Phase 1 | 21 | Ascendo Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06298058 | A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. | recruiting | Phase 1 | 144 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06512116 | A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients. | recruiting | Phase 1 | 196 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07232407 | A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07274852 | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05584800 | Study of ZGGS18 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 222 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06938880 | Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07124117 | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | OBI Pharma, IncINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT07252414 | GenSci143 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07310134 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07232524 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 16 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06368921 | A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06882135 | HW071021 Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 76 | Wuhan Humanwell Innovative Drug Research and Development Center Limited CompanyINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2026source: clinicaltrials